A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3
Phase of Trial: Phase III
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 10 Sep 2018 This trial was discontinued in Portugual (End date: 2018-07-11).
- 27 Apr 2018 Status has been changed to recruiting.
- 26 Apr 2018 New trial record